Showing 4981-4990 of 7371 results for "".
- Biosimilar Update: Dr. Reddy’s Completes Phase I Study of Proposed Tocilizumab Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-dr-reddys-completes-phase-i-study-of-proposed-tocilizumab-biosimilar/2461765/Dr. Reddy’s Laboratories’ tocilizumab biosimilar candidate, DRL_TC, met its primary and secondary endpoints in a Phase I study. The company is now initiating a global Phase III study with the aim of comparing the efficacy, safety, tolerability and immunogeni
- Sol-Gel, Searchlight Pharma Partner to Commercialize TWYNEO and EPSOLAY in Canadahttps://practicaldermatology.com/news/sol-gel-searchlight-pharma-partner-to-commercialize-twyneo-and-epsolay-in-canada/2461764/Israel’s Sol-Gel Technologies, Ltd. and Searchlight Pharma Inc. have signed exclusive license agreements for TWYNEO and EPSOLAY for the Canadian market. Both products recently launched in the U.S., and Searchlight is to commercialize in Canada over a fifteen-year term that i
- Programmable 3D-printed Wound Dressing Could Improve Treatment for Burns and Aid Drug Deliveryhttps://practicaldermatology.com/news/programmable-3d-printed-wound-dressing-could-improve-treatment-for-burns-and-aid-drug-delivery/2461762/A 3D-printed wound dressing that uses advanced polymers may enhance the healing process for burn patients, aid drug delivery in cancer treatment, and help customize skin care regimens. "To treat burn victims, we can customize the shape using a 3D printer, secondly, t
- Researchers Uncover Clues Driving PsO Spread and Severityhttps://practicaldermatology.com/news/researchers-uncover-clues-driving-pso-spread-and-severity/2461759/New research sheds light on the cellular changes that drive psoriasis severity and also offers important clues about how the disease spreads to other parts of the body. Specifically, the location of clusters of fibroblasts and macrophages tend to occur more commonly in the upper l
- TWi Biotechnology, Yale University Seek Participants With GA for Phase 1 trial of a Topical JAK Inhibitorhttps://practicaldermatology.com/news/twi-biotechnology-yale-university-seek-participants-with-ga-for-phase-1-trial-of-a-topical-jak-inhibitor/2461757/TWi Biotechnology (TWiB) is seeking participants for a Phase 1 clinical trial of a topical gel form of tofacitinib for the treatment of granuloma annulare (GA). Individuals with GA or friends and family members can find study information at:
- EULAR News: Tremyfa Data Shows Sustained Improvements in PsAhttps://practicaldermatology.com/news/eular-news-tremyfa-data-showing-sustained-improvements-in-psa/2461755/Tremfya (guselkumab) provides sustainable improvements in all minimal disease activity (MDA) domains through week 48 in adults with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR), according to new data
- Sun Pharma’s Ilumetri (Tildrakizumab Injection) Scores Nod For Plaque Psoriasis in Chinahttps://practicaldermatology.com/news/sun-pharmas-ilumetri-tildrakizumab-injection-scores-nod-for-plaque-psoriasis-in-china/2461753/The New Drug Application (NDA) of tildrakizumab injection under the brand name of Ilumetri has been approved by the National Medical Products Administration of the People’s Republic of China, Sun Pharma reports. Ilumetri is indicated for the treatment of adults wit
- Nivea's Skin Out Loud Series Tackles Skin Diversityhttps://practicaldermatology.com/news/niveas-skin-out-loud-series-tackles-skin-diversity/2461751/Nivea is rolling out a five-episode "Skin Out Loud" series. The series features a diverse cast of hosts including TV Host Milka Loff Fernandes, Brigiding from RuPaul's Drag Race Philippines, South African skinfluencer Zithobe
- DermBiont's 0.8% SM-030 Topical Gel Fades Solar Lentigos, Normalizes Pigmentation in Phase 2 Studyhttps://practicaldermatology.com/news/dermbionts-08-sm-030-topical-gel-fades-solar-lentigos-normalizes-pigmentation-in-phase-2-study/2461748/DermBiont’s 0.8% SM-030 gel performed well in a Phase 2 trial treating solar lentigos and normalizing pigmentation of the skin, the Company reports. SM-030 is a first-in-class selective and potent topical PKCβ inhibitor intended to reduce the production of epidermal mela
- Lumohs, George Tiemann and Company Join Forces to Distribute Lumohs’ Illuminating Devicehttps://practicaldermatology.com/news/lumohs-george-tiemann-and-company-join-forces-to-distribute-lumohs-illuminating-device/2461747/Nano Surgical is partnering with George Tiemann and Company, to bring Lumohs’ illuminating device to dermatology market. Lumohs is a patented, reusable scalpel handle that provides integrated shadowless illumination of the surgical site. With no light obstructions between th